Zacks Research Lifts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED - Free Report) - Research analysts at Zacks Research lifted their FY2025 earnings estimates for shares of Globus Medical in a note issued to investors on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical device company will post earnings of $3.43 per share for the year, up from their prior estimate of $3.42. The consensus estimate for Globus Medical's current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical's Q4 2026 earnings at $0.97 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. The company had revenue of $625.71 million during the quarter, compared to analysts' expectations of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The business's quarterly revenue was up 63.1% on a year-over-year basis. During the same period last year, the business earned $0.57 EPS.

Other research analysts have also issued research reports about the stock. Royal Bank of Canada increased their target price on shares of Globus Medical from $80.00 to $92.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 6th. Needham & Company LLC restated a "hold" rating on shares of Globus Medical in a research report on Thursday, January 9th. Canaccord Genuity Group boosted their target price on shares of Globus Medical from $92.00 to $101.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Morgan Stanley upgraded shares of Globus Medical from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $83.00 to $100.00 in a research report on Monday, December 2nd. Finally, Truist Financial raised their price objective on Globus Medical from $85.00 to $90.00 and gave the company a "hold" rating in a research note on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $96.91.

Globus Medical Stock Down 1.0 %

Shares of GMED traded down $0.90 during trading hours on Thursday, hitting $92.42. The company had a trading volume of 950,766 shares, compared to its average volume of 1,375,836. Globus Medical has a 12 month low of $49.33 and a 12 month high of $93.67. The business has a fifty day moving average of $84.64 and a 200-day moving average of $76.45. The firm has a market cap of $12.59 billion, a price-to-earnings ratio of 137.94, a PEG ratio of 1.76 and a beta of 1.19.

Insider Activity

In other Globus Medical news, SVP Kelly Huller sold 2,500 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total transaction of $217,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel T. Scavilla sold 60,000 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 81,667 shares of company stock worth $6,674,554. 18.54% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GMED. Swedbank AB raised its holdings in Globus Medical by 18.9% in the fourth quarter. Swedbank AB now owns 475,489 shares of the medical device company's stock worth $39,328,000 after buying an additional 75,489 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Globus Medical by 1.5% in the 4th quarter. Pacer Advisors Inc. now owns 24,792 shares of the medical device company's stock worth $2,051,000 after acquiring an additional 370 shares during the last quarter. KBC Group NV lifted its position in Globus Medical by 1.5% in the 4th quarter. KBC Group NV now owns 46,183 shares of the medical device company's stock valued at $3,820,000 after acquiring an additional 678 shares in the last quarter. Encompass More Asset Management purchased a new stake in Globus Medical during the 4th quarter valued at $545,000. Finally, Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Globus Medical by 0.3% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 415,241 shares of the medical device company's stock worth $34,345,000 after purchasing an additional 1,130 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.